Technical Perspectives on Generic Drugs Stocks -- Fibrocell Science, Galectin Therapeutics, Agile Therapeutics, and Zynerba Pharma

Friday, January 19, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 19, 2018 /PRNewswire/ -- strives to bring the best free research to the investment

community. Today we are offering reports on FCSC, GALT, AGRX, and ZYNE which can be accessed for free by signing up to Pre-market today, covers the Generic Drugs space, which comprises
firms primarily engaged in the development, manufacture, and marketing of generic drugs. The industry is fragmented and affected by government regulations in different regions and countries. Lined up for assessment this morning are the following stocks: Fibrocell Science Inc. (NASDAQ: FCSC), Galectin Therapeutics Inc. (NASDAQ: GALT), Agile Therapeutics Inc. (NASDAQ: AGRX), and Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE). All you have to do is sign up today for this free limited time offer by clicking the link below.

Fibrocell Science

Shares in Exton, Pennsylvania-based Fibrocell Science Inc. saw a drop 5.32%, ending Thursday's trading session at $0.75. The stock recorded a trading volume of 847,679 shares, which was higher than its three months average volume of 553,170 shares. The Company's shares have gained 12.71% in the last month. The stock is trading 31.24% below its 50-day moving average. Moreover, shares of Fibrocell Science, which focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the US, have a Relative Strength Index (RSI) of 43.34.

On January 16th, 2018, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $7.60 a share to $6 a share. Get the full research report on FCSC for free by clicking below at:

Galectin Therapeutics

Norcross, Georgia-based Galectin Therapeutics Inc.'s stock declined 2.68%, closing the day at $5.81. A total volume of 959,047 shares was traded, which was above their three months average volume of 888,410 shares. The Company's shares have skyrocketed 147.23% in the past month, 153.71% in the previous three months, and 469.61% over the past year. The stock is trading 89.53% and 129.48% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Galectin Therapeutics, which engages in the research and development of therapies for fibrotic disease and cancer, have an RSI of 70.07. Access the free research report on GALT now by signing up at:

Agile Therapeutics

On Thursday, shares in Princeton, New Jersey headquartered Agile Therapeutics Inc. recorded a trading volume of 314,241 shares. The stock ended the day 4.52% higher at $3.47. The Company's shares have surged 42.21% over the past year. The stock is trading below its 200-day moving average by 11.81%. Furthermore, shares of Agile Therapeutics, which focuses on the development and commercialization of prescription contraceptive products for women, have an RSI of 49.13.  

On December 22nd, 2017, Agile Therapeutics announced that the US FDA issued a complete response letter (CRL) in response to the New Drug Application (NDA) resubmission for the Company's investigational non-daily, low-dose combination hormonal contraceptive patch, Twirla (AG200-15). The CRL states that the FDA has determined that it cannot approve the NDA in its present form.

On December 26th, 2017, research firm William Blair downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Are you already registered with Wall St. Equities? Do so now for free, and get the report on AGRX at:

Zynerba Pharmaceuticals

Devon, Pennsylvania headquartered Zynerba Pharmaceuticals Inc.'s stock dropped slightly by 0.61%, finishing yesterday's session at $11.43 with a total trading volume of 229,604 shares. The Company's shares have advanced 22.64% in the previous three months. The stock is trading below its 50-day moving average by 8.21%. Additionally, shares of Zynerba Pharma, which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery, have an RSI of 41.41.  

On January 03rd, 2018, Zynerba Pharma announced that it will concentrate its focus on rare and near-rare neurological and psychiatric disorders with high unmet medical needs. In 2018, the Company intends to develop ZYN002 in a pivotal Phase-2/3 program in Fragile X syndrome and in Phase-2 programs in refractory epilepsies, including adult refractory focal epilepsy and developmental and epileptic encephalopathies in pediatric and adolescent patients. Additionally, the Company plans to initiate Phase-2 development of ZYN001 in Tourette Syndrome by year end 2018. Aspiring Member, please take a moment to register below for your free research report on ZYNE at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store